(Q44610473)

4 December 2017

title

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia (English)

1 reference

4 December 2017

0 references

1 reference

1

1 reference

4 December 2017

Hutchinson M

2

1 reference

4 December 2017

Larsen JP

series ordinal

3

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

International Journal of Geriatric Psychiatry

4 December 2017

published in

1 reference

4 December 2017

volume

18

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

937-941

1 reference

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

4 December 2017

cites work

1 reference

Development of daytime somnolence over time in Parkinson's disease

21 January 2018

1 reference

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

Cholinergic dysfunction in diseases with Lewy bodies.

21 January 2018

1 reference

Fluctuations in attention: PD dementia vs DLB with parkinsonism

21 January 2018

1 reference

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

21 January 2018

1 reference

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

7 January 2021

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

7 January 2021

Parkinson's disease, smoking and family history: meta-analysis

1 reference

7 January 2021

Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex.

1 reference

7 January 2021

Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease

1 reference

7 January 2021

1 reference

7 January 2021

Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists

1 reference

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

7 January 2021

Cholinesterase inhibition in Parkinson's disease

1 reference

7 January 2021

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.

1 reference

7 January 2021

Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies

1 reference

7 January 2021

Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease.

1 reference

7 January 2021

Acetylcholine in mind: a neurotransmitter correlate of consciousness?

1 reference

7 January 2021

Clinical neurochemistry: developments in dementia research based on brain bank material

1 reference

7 January 2021

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

1 reference

7 January 2021

Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease.

1 reference

7 January 2021

Basal forebrain neurons in the dementia of Parkinson disease

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.949

1 reference

4 December 2017

1 reference